Compare Alcon AG (ALC) vs Lemonade Inc (LMND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Lemonade Inc — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while Lemonade Inc trades at $70.95 (market cap $5.96B). The key difference: Alcon AG is far larger — about 5.5× Lemonade Inc's market cap, and Alcon AG pays a 0.54% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals.
| ALC | LMND | |
|---|---|---|
Market Cap | $32.69B | $5.96B |
Sector | Health | Financials |
52-Week High | $92.22 | $96.57 |
52-Week Low | $62.02 | $36.28 |
Enterprise Value | $36.28B | $5.79B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Lemonade (LMND) trades at $77.59, up 8.49% in the last session, showing strong momentum with a bullish technical outlook. The stock has consistently beaten earnings expectations in recent quarters, with revenue growth accelerating from $257M in 2022 to $738M in 2025. However, the company remains unprofitable with a -16.44% net income margin, though losses are narrowing. Recent expansion into new states and reinsurance program improvements provide positive catalysts.
While LMND shows promising growth and technical strength, the stock trades above the $71.75 analyst consensus target. The path to profitability remains the key challenge, with negative cash flow from operations and high valuation multiples creating risk. Investors face a trade-off between strong revenue growth and persistent losses in a competitive insurance market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
